{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1683232200, "earningsTimestampStart": 1690887540, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.63, "epsForward": -0.8, "epsCurrentYear": -0.46, "priceEpsCurrentYear": -1.423913, "sharesOutstanding": 26443600, "bookValue": 1.01, "fiftyDayAverage": 0.6658, "fiftyDayAverageChange": -0.010800004, "fiftyDayAverageChangePercent": -0.016221095, "twoHundredDayAverage": 0.98729, "twoHundredDayAverageChange": -0.33229005, "twoHundredDayAverageChangePercent": -0.33656782, "marketCap": 18101318, "forwardPE": -0.81874996, "priceToBook": 0.6485148, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 1.1114453, "regularMarketPrice": 0.655, "firstTradeDateMilliseconds": 1601040600000, "priceHint": 4, "exchange": "NCM", "shortName": "GeoVax Labs, Inc.", "longName": "GeoVax Labs, Inc.", "messageBoardId": "finmb_12056751", "regularMarketChange": 0.007199943, "regularMarketTime": 1684180804, "regularMarketDayHigh": 0.67, "regularMarketDayRange": "0.635 - 0.67", "regularMarketDayLow": 0.635, "regularMarketVolume": 76769, "regularMarketPreviousClose": 0.6478, "bid": 0.0, "ask": 0.0, "bidSize": 13, "askSize": 11, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.642, "averageDailyVolume3Month": 290528, "averageDailyVolume10Day": 232500, "fiftyTwoWeekLowChange": 0.12399995, "fiftyTwoWeekLowChangePercent": 0.23352157, "fiftyTwoWeekRange": "0.531 - 4.3", "fiftyTwoWeekHighChange": -3.6450002, "fiftyTwoWeekHighChangePercent": -0.8476744, "fiftyTwoWeekLow": 0.531, "fiftyTwoWeekHigh": 4.3, "dividendDate": 1600992000, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "GeoVax Labs", "symbol": "GOVX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1900 Lake Park Drive", "address2": "Suite 380", "city": "Smyrna", "state": "GA", "zip": "30080", "country": "United States", "phone": "(678) 384-7220", "fax": "(678) 384-7281", "website": "https://www.geovax.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Mr. David Alan Dodd", "age": 72, "title": "Chairman, Pres & CEO", "yearBorn": 1950, "fiscalYear": 2022, "totalPay": {"raw": 469015, "fmt": "469.01k", "longFmt": "469,015"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark W. Reynolds CPA, CPA", "age": 60, "title": "CFO & Corp. Sec.", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 348200, "fmt": "348.2k", "longFmt": "348,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark J. Newman Ph.D.", "age": 67, "title": "Chief Scientific Officer", "yearBorn": 1955, "fiscalYear": 2022, "totalPay": {"raw": 364166, "fmt": "364.17k", "longFmt": "364,166"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Harriet Latham Robinson Ph.D.", "age": 84, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1938, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kelly T. McKee Jr., M.D., M.P.H.", "age": 72, "title": "Chief Medical Officer", "yearBorn": 1950, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jeffrey  Welch", "title": "Head of Process Devel. & Manufacturing Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}